Your Child's Care Begins Here
Our Haworth Innovative Therapeutics Clinic serves as the headquarters for an international network of researchers in high-risk childhood cancers, called the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), offering young patients access to clinical trials and the latest treatment strategies for neuroblastoma. We offer phase I and phase II trials that include a sophisticated gene analysis of a tumor sample so that treatment can be designed specifically for each individual child. If surgery is needed as part of treatment, we collaborate with our pediatric surgeons, who are skilled at helping kids of all ages.
Treatments We Provide
Your child will likely require chemotherapy before and/or after surgery. If the primary tumor cannot be removed surgically, chemotherapy may become the main treatment.
Radiation uses powerful X-rays to destroy neuroblastoma cells remaining after chemotherapy and surgery.
Special antibodies are used to direct and stimulate the immune system so it can attack the neuroblastoma cancer cells.
Most children with neuroblastoma will need the primary tumor removed surgically. Surgery is sometimes the only treatment needed if tumors are small and the cancer hasn't spread.
In children with high-risk neuroblastoma, a drug related to vitamin A can help cancer cells turn into mature nerve cells, and prevent the cancer from growing or spreading.
Helen DeVos Children's Hospital leads a group, the NMTRC, of children's hospitals and universities working to develop new ways to treat neuroblastoma. Your child may be a candidate for our phase I and II clinical trials.